Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells

Many breast cancer deaths result from tumors acquiring resistance to available therapies. Thus, new therapeutic agents are needed for targeting drug-resistant breast cancers. Drug-refractory breast cancers include HER2+ tumors that have acquired resistance to HER2-targeted antibodies and kinase inhi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2017-04, Vol.8 (17), p.28971-28989
Hauptverfasser:	Ferreira, Renan B, Wang, Mengxiong, Law, Mary E, Davis, Bradley J, Bartley, Ashton N, Higgins, Paul J, Kilberg, Michael S, Santostefano, Katherine E, Terada, Naohiro, Heldermon, Coy D, Castellano, Ronald K, Law, Brian K
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - chemical synthesis Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Breast - pathology Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cell Line, Tumor Cell Proliferation - drug effects Down-Regulation Drug Resistance, Neoplasm - drug effects Female HEK293 Cells Humans Mechanistic Target of Rapamycin Complex 1 - metabolism Mice Mice, Inbred NOD Mice, SCID Phosphorylation Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins c-akt - metabolism Receptor, Epidermal Growth Factor - metabolism Receptor, ErbB-2 - metabolism Receptor, ErbB-3 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Research Paper Signal Transduction - drug effects Unfolded Protein Response - drug effects Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!